Professor of Medicine, Ohio State University
Hematology
Dr. Michael R. Grever, MD
|
|
Give Review
Doctor Michael R. Grever, MD practices Hematology. He studied medicine at University of Pittsburgh School of Medicine. He received awards:"America's Top Doctors", "America's Top Doctors for Cancer" and "CMS Meaningful Use Stage 1 Certification". Michael Grever is also a published physician. He has 99 paper published. The most recent paper is: Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients.
Publications
- Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients.
- Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
- Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludara...
- Dinaciclib is a novel cyclin dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia.
- Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.
- Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.
- Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective.
- A Phase 1 Trial of Single Agent Reolysin in Patients with Relapsed Multiple Myeloma.
- Hairy cell leukemia: Update on molecular profiling and therapeutic advances.
- Sorbicillinoid analogs with cytotoxic and selective anti-Aspergillus activities from Scytalidium album.
- Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.
- The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease.
- Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.
- Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.
- Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center.
- A phase I trial of flavopiridol in relapsed multiple myeloma.
- Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory Non-Hodgkin's Lymphoma.
- Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.
- Standard Pentostatin Dose Reductions in Renal Insufficiency Are Not Adequate: Selected Patients with Steroid-Refractory Acute Graft-Versus-Host Disease.
- Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia.
- A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol.
- Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer.
- In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid L...
- A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
- Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia.
- A Dose Escalation and Pharmacodynamic Study of Triapine and Radiation in Patients With Locally Advanced Pancreas Cancer.
- Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol.
- Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
- Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.
- ER stress and autophagy: new players in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.
- Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features.
- The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leuke...
- Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia.
- Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide-CCI-779 Interaction via P-Glycoprotein.
- Incidence of Therapy-related Myeloid Neoplasia after Initial Therapy for CLL with Fludarabine-Cyclophosphamide versus Fludarabine: Long-Term Follow-up of US Intergroup...
- Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells.
- Characterization of Silvestrol Pharmacokinetics in Mice Using Liquid Chromatography-Tandem Mass Spectrometry.
- Modern strategies for hairy cell leukemia.
- Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
- A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.
- Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia.
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
- Flavopiridol, fludarabine, and rituximab in mantle cell Lymphoma and indolent B-cell lymphoproliferative disorders.
- How I treat hairy cell leukemia.
- The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.
- Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.
- Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.
- The anticipated physician shortage: meeting the nation's need for physician services.
- Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patie...
- A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.
- A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels.
- The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.
- Phase II trial of sorafenib in metastatic thyroid cancer.
- Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
- Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.
- Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
- Flavopiridol in chronic lymphocytic leukemia: a concise review.
- Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.
- Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in hum...
- Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.
- Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
- A phase I and pharmacokinetic study of weekly oxaliplatin followed by paclitaxel in patients with solid tumors.
- Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium.
- Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria.
- Flavopiridol in the treatment of chronic lymphocytic leukemia.
- Community-based phase II trial of PCR for CLL/SLL patients.
- Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
- Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality.
- Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia.
- Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia.
- Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytot...
- Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III T...
- Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial...
- Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocyt...
- Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untre...
- Pentostatin: impact on outcome in hairy cell leukemia.
- Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.
- Treatment of relapsed chronic lymphocytic leukemia: old and new therapies.
- Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justificatio...
- Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent Lymphoma and chronic lymphocytic leukemia.
- Changing the way we think about chronic lymphocytic leukemia.
- TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia.
- Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical ac...
- Pentostatin in steroid-refractory acute graft-versus-host disease.
- A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
- Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
- Combination immunotherapy of B-cell non-Hodgkin's Lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
- Antibody therapy for chronic lymphocytic leukemia: a promising new modality.
- Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.
- Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation.
- New drugs in acute myeloid leukemia.
- Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8...
- KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of ap...
- Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
- Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
- PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.).
- A Phase I Dose Escalation and Pharmacodynamic Study of SU5416 (Semaxanib) Combined with Weekly Cisplatin and Irinotecan in Patients with Advanced Solid Tumors.
- Therapeutic Potential of the Translation Inhibitor Silvestrol in Hepatocellular Cancer.
Schools
University of Pittsburgh School of Medicine
Presby University Hospital
Ohio State University
Conditions Treated
- Anemia
- Lymphoma
- Non-Hodgkin's Lymphoma
- Soft Tissue Sarcoma
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
Education
-
Ohio State University Hospital -
University of Pittsburgh Medical Center -
University of Pittsburgh School of Medicine
Hospital
-
Ohio State University Wexner Medical Center
Helpful Reviews
Similar Doctors
|
Dr. Spero R. Cataland, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. John C. Byrd, MD |
|
Dr. Leslie A. Andritsos, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Thomas M. Davis, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Yvonne A. Efebera, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Don M. Benson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kami J. Maddocks-Christianson, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Robert Wesolowski, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Robert A. Baiocchi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathon B. Cohen, MD |
|
|
Dr. Brent C. Behrens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James S. Blachly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew V. Grainger, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Robert D. Rupert Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. William G. Blum, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Amir Mortazavi, MD |
|
|
Dr. Monroe D. Dowling Jr., MD
This Doctor is OpenDoctor Recommended.
|